financetom
Business
financetom
/
Business
/
Surf Air Mobility Stock Gains On Q4 Earnings - Here's Why
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Surf Air Mobility Stock Gains On Q4 Earnings - Here's Why
Mar 28, 2024 1:45 PM

Surf Air Mobility Inc. ( SRFM ) reported its fourth-quarter financial results after the bell Thursday.

Surf Air Mobility ( SRFM ) reported quarterly non-GAAP losses of 28 cents per share, which was in line with consensus, and quarterly revenue of $26.8 million. Pro Forma revenue came in at $27.4 million, beating the $25.69 million estimate.

The company reported fiscal year 2023 losses of $6.35 per share, compared to losses of $5.51 from the prior year.

"We are pleased to have beat our revenue guidance and achieved our Adjusted EBITDA guidance for the year. Additionally, we've achieved two significant milestones: our direct listing on the NYSE and the completion of our merger with Southern Airways. We have also advanced our growth pillars of expanding our leading regional airline network and developing a proprietary powertrain technology to electrify smaller aircraft," said Stan Little, Surf Air Mobility's ( SRFM ) CEO.

Outlook: Surf Air Mobility ( SRFM ) sees first-quarter revenue in the range of $28.5 million to $29.5 million, versus the $32.3 million estimate. The company will provide full-year 2024 guidance at its Investor Day, which will be held on June 7 at the New York Stock Exchange.

"Looking ahead in 2024 we are focused on balancing growth with profitability, expense reduction, and disciplined capital allocation centered around high ROI opportunities, including potential route expansions," Surf Air Mobility CFO Oliver Reeves stated.

Related News: What's Going On With Medical Properties Trust Stock?

Price Action: SRFM shares were up 4.39% at $0.88 in the after-hours session on the last check Thursday.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Crypto-focused Grayscale makes US IPO filing public
Crypto-focused Grayscale makes US IPO filing public
Nov 13, 2025
Nov 13 (Reuters) - Crypto-focused asset manager Grayscale on Thursday publicly filed its paperwork for an initial public offering in the United States. (Reporting by Arasu Kannagi Basil in Bengaluru) ...
Graphite One Identifies Rare Earth Elements at Graphite Creek Deposit in Alaska
Graphite One Identifies Rare Earth Elements at Graphite Creek Deposit in Alaska
Nov 13, 2025
08:55 AM EST, 11/13/2025 (MT Newswires) -- Graphite One ( GPHOF ) said Thursday that it identified the presence of rare earth elements in its Graphite Creek deposit in Alaska. The company said geochemical analyses completed by Activation Laboratories found rare earths in drill core samples of garnet-bearing ore rock within the anticipated pit outlined in a feasibility study completed...
Bausch + Lomb Targets Above-Market Growth, Double-Digit EPS Gains Through 2028
Bausch + Lomb Targets Above-Market Growth, Double-Digit EPS Gains Through 2028
Nov 13, 2025
08:54 AM EST, 11/13/2025 (MT Newswires) -- Bausch + Lomb ( BLCO ) , up 2.4% in U.S. pre-market trading, said Thursday it will present its transformation and growth strategy at an investor day event at the New York Stock Exchange today. The event will focus on the company's rebuilt product pipeline. Total projected peak sales of pipeline products, with...
Xenetic Biosciences Q3 revenue up 67.2% on royalty gains
Xenetic Biosciences Q3 revenue up 67.2% on royalty gains
Nov 13, 2025
Overview * Xenetic Q3 revenue rises 67.2% yr/yr, driven by increased royalty revenue * Net loss for Q3 2025 was $0.5 mln, with increased R&D expenses * Company secured $3.9 mln from October 2025 offering to extend cash runway Outlook * Xenetic advances DNase technology towards Phase 1 clinical trials for solid tumors * Company plans to invest in pre-clinical...
Copyright 2023-2026 - www.financetom.com All Rights Reserved